Literature DB >> 7714086

Oral contraceptive pills, gonadotropin-releasing hormone agonists, or use in combination for treatment of hirsutism: a clinical research center study.

B R Carr1, N A Breslau, C Givens, W Byrd, C Barnett-Hamm, P B Marshburn.   

Abstract

The effectiveness of oral contraceptive pills (OCPs), GnRH agonist (GnRH-a), and a combination of OCPs and GnRH-a in the treatment of hirsute women was compared and the impact of these treatments on hormonal and Ca metabolism was investigated. Thirty-three women were prospectively enrolled and randomized into three treatment groups (11 in each group). The serum levels of LH, estradiol, testosterone, free testosterone, androstenedione, and 17-hydroxyprogesterone declined in all 3 treatment groups, whereas the inclusion of GnRH-a treatment tended to promote a more rapid decrease in these hormone levels. Total cholesterol, low density lipoprotein, and high density lipoprotein levels remained unchanged. The assessment of hirsutism by the Ferriman-Gallwey score revealed a similar 25% reduction in score by all three treatment groups by 6 months. In addition, no difference was detected between groups with respect to hair diameters and the vellus index. Clinical assessment of hirsutism at 3 months by the patients revealed that the GnRH-a and the OCPs-plus-GnRH-a groups had better responses than the group on OCPs alone, but by 6 months all three groups were similar. The symptoms of hot flashes and vaginal dryness were greatest in subjects treated with GnRH-a alone. Serum Ca, phosphorus, alkaline phosphatase, osteocalcin, and 2-h fasting and 24-h urinary Ca excretion levels all increased significantly in subjects treated with the GnRH-a alone, whereas a decrement or no changes occurred for these measurement in the other two groups. The estimated Ca balance was unchanged in the OCPs and the OCPs-plus-GnRH-a groups but declined by 90 mg/day from baseline in the GnRH-a-treated women (p < or = 0.001). Bone density significantly decreased in the lumber spine in women treated with GnRH-a alone, with a less marked decline in the femoral neck. In contrast, women receiving OCPs plus GnRH had increased bone density in the lumbar spine. It is concluded that: 1) clinical measures of hirsutism are not different after 6 months of treatment with OCPs alone, GnRH-a alone, or a combination of the two; 2) the decline in gonadotropins and steroid hormones and improvement in clinical response were more rapid and pronounced when GnRH-a treatment was added to OCP administration; and 3) the negative impact of GnRH-a alone on Ca balance and bone loss limits its usefulness as a single agent for long-term therapy of hirsutism.

Entities:  

Keywords:  Americas; Androgens; Biology; Comparative Studies; Contraception; Contraceptive Methods--therapeutic use; Developed Countries; Diseases; Endocrine System; Family Planning; Gonadotropins; Gonadotropins, Chorionic--therapeutic use; Hirsutism; Hormones; North America; Northern America; Oral Contraceptives--therapeutic use; Physiology; Research Methodology; Research Report; Signs And Symptoms; Skeletal Effects; Studies; Treatment; United States

Mesh:

Substances:

Year:  1995        PMID: 7714086     DOI: 10.1210/jcem.80.4.7714086

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

Review 1.  Hormonal Contraceptives and Dermatology.

Authors:  Natalie M Williams; Michael Randolph; Ali Rajabi-Estarabadi; Jonette Keri; Antonella Tosti
Journal:  Am J Clin Dermatol       Date:  2021-01       Impact factor: 7.403

2.  The use of a combined regimen of GnRH agonist plus a low-dose oral contraceptive improves the spontaneous pulsatile LH secretory characteristics in patients with polycycstic ovary disease after discontinuation of treatment.

Authors:  A D Genazzani; C Battaglia; O Gamba; F Petraglia; B Malavasi; A R Genazzani
Journal:  J Assist Reprod Genet       Date:  2000-05       Impact factor: 3.412

3.  Gonadotropin-releasing hormone agonists administration in polycystic ovary syndrome. Effects on bone mass.

Authors:  G Lupoli; C Di Carlo; V Nuzzo; G Vitale; D Russo; S Palomba; C Nappi
Journal:  J Endocrinol Invest       Date:  1997-09       Impact factor: 4.256

4.  Effect of finasteride in idiopathic hirsutism.

Authors:  E Faloia; S Filipponi; V Mancini; S Di Marco; F Mantero
Journal:  J Endocrinol Invest       Date:  1998-11       Impact factor: 4.256

5.  Polymorphisms of estrogen receptor beta gene are associated with hypospadias.

Authors:  A Beleza-Meireles; D Omrani; I Kockum; L Frisén; K Lagerstedt; A Nordenskjöld
Journal:  J Endocrinol Invest       Date:  2006-01       Impact factor: 4.256

6.  Acute goserelin administration inhibits gonadotropin and androgen secretion in post-menopausal women with ovarian hyperandrogenism.

Authors:  C Di Bisceglie; L Brocato; M Tagliabue; A Bertagna; L Gianotti; E Ghigo; C Manieri
Journal:  J Endocrinol Invest       Date:  2003-03       Impact factor: 4.256

7.  Gonadotropin releasing hormone agonists: Expanding vistas.

Authors:  Navneet Magon
Journal:  Indian J Endocrinol Metab       Date:  2011-10

8.  Consensus Statement on the Use of Oral Contraceptive Pills in Polycystic Ovarian Syndrome Women in India.

Authors:  Duru Shah; Madhuri Patil
Journal:  J Hum Reprod Sci       Date:  2018 Apr-Jun
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.